Aksel Siva (EAN Programme Committee; Professor of Neurology, Istanbul University, Cerrahpasa School of Medicine, Turkey) talks to us about various treatment considerations in multiple sclerosis (MS): induction, individualised therapy, optimal therapeutic window and when to switch therapies. Part 1 of 2.
1. What are the limitations of using induction therapy in multiple sclerosis (MS)? (0:12)
2. Given the lack of biomarkers, what features of MS do you consider most important to establish an individual treatment regimen? (3:23)
View Part 2 here.
Speaker disclosure: Aksel Siva has nothing to disclose in relation to this video interview.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.